Late Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial. The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data. We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.
By April, U.S. officials at the NSC and the State Department had begun to compile circumstantial evidence that the WIV lab, rather than the seafood market, was actually the source of the virus. The former explanation for the outbreak was entirely plausible, they felt, whereas the latter would be an extreme coincidence. But the officials couldn’t say that out loud because there wasn’t firm proof either way. And if the U.S. government accused China of lying about the outbreak without firm evidence, Beijing would surely escalate tensions even more, which meant that Americans might not get the medical supplies that were desperately needed to combat the rapid spread of SARS-CoV-2 in the United States.
We call for collaborative efforts from scientists, manufacturers, and regulators to assess such risks and look for viable methods to reducing micro(nano)plastics and other respirable debris in face masks and respirators worn by a large population worldwide during the current pandemic.
Italian scientists say sewage water from two cities contained coronavirus traces in December, long before the country’s first confirmed cases.
The National Institute of Health (ISS) said water from Milan and Turin showed genetic virus traces on 18 December.
It adds to evidence from other countries that the virus may have been circulating much earlier than thought.